Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review
Qin Hu,Jinglan Chen,Shusen Sun,Sheng Deng
DOI: https://doi.org/10.2147/IDR.S390635
2022-11-29
Infection and Drug Resistance
Abstract:Qin Hu, 1– 4, &ast Jinglan Chen, 1, 2, 5, &ast Shusen Sun, 1, 6 Sheng Deng 1, 2, 5 1 Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, People's Republic of China; 2 Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, People's Republic of China; 3 Hospital Institute Administration, Central South University, Changsha, People's Republic of China; 4 Xiangya Health Development Research Center, Changsha, People's Republic of China; 5 The Hunan Institute of Pharmacy Practice and Clinical Research, Changsha, People's Republic of China; 6 Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Western New England University, Springfeld, MA, USA &astThese authors contributed equally to this work Correspondence: Sheng Deng, Email Objective: Carbapenem-resistant Enterobacteriaceae (CRE) has become a significant public health problem in the last decade. We aimed to explore the risk factors of mortality in patients with CRE infections and to focus on the current evidence on antimicrobial regimens for CRE infections, particularly from the perspective of mortality. Methods: A systematic literature review was performed by searching the databases of EMBASE, PubMed, and the Cochrane Library to identify studies that evaluated mortality-related risk factors and antimicrobial regimens for CRE infections published from 2012 to 2022. Results: In total, 33 and 28 studies were included to analyze risk factors and antibiotic treatment, respectively. The risk factors most frequently reported as significantly associated with CRE mortality were antibiotic use (92.9%; 26/28 studies), comorbidities (88.7%; 23/26 studies), and hospital-related factors (82.8%; 24/29 studies). In 10 studies that did not contain ceftazidime/avibactam (CAZ-AVI) therapy, seven demonstrated significantly lower mortality in combination therapy than in monotherapy. However, 5 of 6 studies identified no substantial difference between CAZ-AVI monotherapy and CAZ-AVI combination therapy. Six studies reported substantially lower mortality in CAZ-AVI regimens than in other regimens. Conclusion: Several risk factors, particularly antibiotic use and patients' comorbidities, are strong risk factors for CRE mortality. The optimal regimen for CRE infections remains controversial. Combination therapy should be considered when carbapenems, colistin, tigecycline, or aminoglycosides are administered. CAZ-AVI appears to be a promising antibiotic for CRE infections. Most importantly, treatment should be individualized according to the source and severity of the disease or other highly related risk factors. Keywords: carbapenem resistant Enterobacteriaceae, CRE, mortality, risk factors, antimicrobial, treatment The global emergence of antimicrobial resistance poses a threat to human health. 1 Carbapenem-resistant Enterobacteriaceae (CRE) or carbapenemase-producing Enterobacteriaceae (CPE) are Gram-negative bacteria that are resistant to the carbapenem drug class. 2 The major resistance mechanisms of CRE are: enzyme production, efflux pumps and porin mutations. 3 Of these, the production of carbapenemase including KPC, NDM, OXA-48, IMP, and VIM is the main resistance mechanism among CRE. 4 The KPC enzyme accounts for a high proportion and has the ability to hydrolyze not just carbapenems but also several other antibiotics, leading to high mortality rate. 5 CRE has become a major public health problem in the last decade due to the gradual increase in carbapenem resistance and the lack of effective antibiotics. 6,7 The infection types of CRE are mainly bloodstream, pneumonia, respiratory, and urinary tract infections (UTIs). CRE infection is associated with increased mortality. 2,6,8 In particular, CRE-caused bloodstream infections (CRE-BSIs) are associated with extremely high mortality, 30%-80%. 9,10 A recent meta-analysis that included 62 studies showed a mortality rate of 54.3% for BSIs and 13.5% for UTIs associated with carbapenem-resistant K. pneumoniae ( CRKP ). 10 Several studies have evaluated risk factors for CRE mortality but results were inconsistent. These risk factors included Pitt bacteremia score, immunocompromised status, previous exposure to carbapenems, lack of infection source control, and inappropriate antibiotic treatment, etc. 11–14 Nevertheless, many studies have considered antibiotic use as significant risk factor -Abstract Truncated-
pharmacology & pharmacy,infectious diseases